asthma – Page 2 – media

AZ and ICL link to research respiratory diseases

AstraZeneca and Imperial College London have announced plans to work together on investigating the scientific mechanisms and underlying drivers of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).
- Source: pharmatimes
- 549
- December 27, 2017
asthma AstraZeneca COPD Market Views
Is Mepolizumab an Effective Treatment for Asthma?

Researchers investigated whether mepolizumab is safer and more effective than triple-inhaled treatments for chronic obstructive pulmonary disease.
- Source: medicalnewsbulletin
- 669
- December 4, 2017
asthma COPD mepolizumab
Ddu College-China’s Import and Export Market Report of Respiratory System Drugs

Respiratory system drugs is a term used to describe a wide variety of medicines used to relieve, treat, or prevent respiratory diseases such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), or pneumonia. Today, Ddu, the leading global pharmaceutical & medical device B2B online platform, will share China’s Import and Export Market Report of Respiratory System Drugs with you.
- Source: Ddu
- 1,315
- November 17, 2017
asthma COPD Ddu College pneumonia respiratory
AstraZeneca-FASENRA Gets US FDA Approval For Severe Eosinophilic Asthma

AstraZeneca and its global biologics research and development arm, MedImmune, said Tuesay that the US Food and Drug Administration has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. FASENRA is not approved for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.
- Source: businessinsider
- 568
- November 15, 2017
asthma eosinophilic Market Views New Approvals
Mobile Digital health has the potential to save $46 billion a year in health spending

Existing digital health products hold the potential to save the nation $46 billion in healthcare spending if they’re deployed comprehensively, according to a new report from IQVIA, which on Tuesday renamed itself from Quintiles/IMS Health.
- Source: healthcareitnews
- 590
- November 9, 2017
asthma cardiac diabetes healthcare Market Views
Sanofi, Regeneron’s biologic shines again in asthma trial

Regeneron and Sanofi have unveiled positive new data from a late-stage trial investigating the biologic dupilumab in adults and adolescents 12 years of age and older with severe, steroid dependent asthma.
- Source: Pharmatimes
- 1,076
- November 3, 2017
asthma Clinical Trial dupilumab
Scientists pinpoint genetic risk factors for asthma, hay fever and eczema

A major international study has pinpointed more than 100 genetic risk factors that explain why some people suffer from asthma, hay fever and eczema.
- Source: Medicalxpress
- 494
- November 1, 2017
asthma eczema genetic risk hay fever Researches
Can an Asthma Drug Help Treat Parkinson’s Disease?

A recent study investigates the ability of an asthma drug to reduce levels of α-synuclein, a protein believed to contribute to the development of Parkinson’s disease.
- Source: medicalnewsbulletin
- 620
- October 18, 2017
asthma disorder Parkinson Researches
Regeneron (REGN) And Sanofi (SNY) Announce Positive Dupilumab Topline Results From Phase III Trial In Uncontrolled Persistent Asthma

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints.
- Source: careers.biospace
- 556
- September 12, 2017
asthma Clinical Trials dupilumab Phase
AstraZeneca announces new mRNA collaboration

A five-year strategic research collaboration between AstraZeneca and its global biologics research and development arm MedImmune and Ethris, a company focussed on mRNA-based therapeutics with specific expertise in pulmonary disease.
- Source: pharmatimes
- 802
- August 22, 2017
asthma chronic collaboration Company Insight mRNA therapy

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.